The Insulin-like Growth Factor Axis and Growth in Children with Chronic Renal Failure: a Report of the Southwest Pediatric Nephrology Study Group
Overview
Authors
Affiliations
Children with chronic renal failure (CRF) are often growth recarded despite normal serum levels of GH and insulin-like growth factors (IGFs). Recent studies suggest that excess IGF-binding proteins (IGFBPs) in the 35-kDa fractions of CRF serum contribute to CRF growth failure. This report characterizes the relationship between IGFBP-3 and IGF peptides in the serum of growth-retarded CRF children. Size-exclusion chromatography at pH 7.4 found IGFBP-3 and IGFs almost exclusively in the 150-kDa fractions of normal serum, where their molar stoichiometry was approximately 1:1. However, similar chromatography of CRF serum found a molar excess of IGFBP-3 over total IGFs in the 150-kDa fractions and large amounts of IGFs in the 35-kDa fractions. In the 150-kDa fractions of CRF serum, IGFBP-3 was present in normal amounts, but a greater than normal amount was in the form of a 29-kDa IGFBP-3 fragment. Treatment of these CRF children with recombinant human GH increased the molar excess of IGFBP-3 over total IGFs in the 150-kDa fractions, the amount of IGFBP-3 and total IGFs in the 150-kDa fractions, and the amount of IGFs, but not IGFBPs, in the 35-kDa fractions. These data suggest that in untreated CRF children, proteolysis of IGFBP-3 in the 150-kDa fractions releases IGFs to the excess IGFBPs in the 35-kDa fractions, but insufficient IGF is released to overcome the growth-inhibiting effects of these excess IGFBPs. Treatment with recombinant human GH increases levels of IGFs and IGFBP-3 in the 150-kDa fractions, and subsequent IGFBP-3 proteolysis releases sufficient IGF to overcome the growth inhibitory effects of excess IGFBPs in the 35-kDa fractions of CRF serum.
Growth Hormone and IGF1 Actions in Kidney Development and Function.
Gurevich E, Segev Y, Landau D Cells. 2021; 10(12).
PMID: 34943879 PMC: 8699155. DOI: 10.3390/cells10123371.
Renal effects of growth hormone in health and in kidney disease.
Haffner D, Grund A, Leifheit-Nestler M Pediatr Nephrol. 2021; 36(8):2511-2530.
PMID: 34143299 PMC: 8260426. DOI: 10.1007/s00467-021-05097-6.
Pubertal development in children with chronic kidney disease.
Haffner D, Zivicnjak M Pediatr Nephrol. 2016; 32(6):949-964.
PMID: 27464647 DOI: 10.1007/s00467-016-3432-3.
Insulin-like growth factor-1 bioactivity plays a prosurvival role in older participants.
Maggio M, Cattabiani C, Lauretani F, Bandinelli S, De Vita F, DallAglio E J Gerontol A Biol Sci Med Sci. 2013; 68(11):1342-50.
PMID: 23671288 PMC: 3805296. DOI: 10.1093/gerona/glt045.
Chronic kidney disease: mineral and bone disorder in children.
Wesseling-Perry K, Salusky I Semin Nephrol. 2013; 33(2):169-79.
PMID: 23465503 PMC: 4209124. DOI: 10.1016/j.semnephrol.2012.12.017.